Laekna Therapeutics ("Laekna"), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised $61 million in Series D financing led by CS Capital with support from Worldstar, and Infinity Capital. Yanchuang Capital as the existing investor continued to support the company with additional funding.